About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, June 18th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

Clean Enviro Tech Corp. (CETC)

HoleinOneStocks.net, PennyStocks24, and BestStocksDaily reported recently on Clean Enviro Tech Corp. (CETC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Clean Enviro Tech Corp. is a development stage technology company based in Las Vegas, Nevada. The Company is an emerging leader in the development and marketing of next generation lithium-ion powered batteries globally. Additionally, the Company is a leading developer of residential, Solar Concentrating, Electric Power Generation Systems that can produce greater than 2,000 watts (2 Kilowatts (kW) of electric power, with zero emissions using sunlight as the only fuel.

Clean Enviro Tech’s shares trade on the OTC Markets’ OTCQB. Founded in 2004, the Company previously went by the name Sky Power Solutions Corp. They changed their name to Clean Enviro Tech Corp. in January of this year.

The Company is focusing their corporate resources and efforts on the development and marketing of lithium-powered vehicles, products and commercial and residential real estate. Clean Enviro Tech has their Concentrating Photovoltaic Solar Parabolic Dish.

The Clean Enviro Tech residential solar power plant has the capacity to save the average user monthly electric power consumption by up to 30-40 percent with zero emissions and zero carbon footprint, using the power of the sun. The Clean Enviro Tech system may be installed easily into most backyards and they take up less than a third of the space of conventional solar panels. The estimation is that the entry level price for a “Skypower Dish” will be $5,000 US upon release.

Last week, Clean Enviro Tech announced that they entered into a Licensing Agreement for manufacturing, marketing as well as distribution rights of the Skypower Dish for India. The Skypower Dish provides a solution for on-grid, off-grid and remote applications for all users that have electricity, no access to electricity, or are experiencing the negative effects of unreliable and intermittent utility service. The unique design of the Skypower Dish gives homeowners access to advanced concentrating Photovoltaic technology combined with sun tracking.

Clean Enviro Tech Corp. (CETC), closed Tuesday's trading session at $1.37, up 8.73%, on 161,031 volume with 175 trades. The average volume for the last 60 days is 53,123 and the stock's 52-week low/high is $0.0041/$4.25.

Los Andes Copper Ltd. (LA.V)

We are highlighting Los Andes Copper Ltd. (LA.V), here at the QualityStocks Daily Newsletter.

Los Andes Copper Ltd. is an exploration and development company with corporate headquarters in Vancouver, British Columbia. The Company is concentrating on the acquisition, exploration and development of advanced stage copper deposits in Latin America. Los Andes is concentrating on the Vizcachitas porphyry copper-molybdenum project located 120 kilometers north of Santiago, Region V, Chile. The Company’s shares trade on the TSX Venture Exchange.

The Vizcachitas project consists of three exploration concessions and 33 exploitation concessions. They cover an area of approximately 59 square kilometers. During 2010, Los Andes Copper fulfilled the requirements of the option agreement and consolidated the property ownership. As a result, the Company now owns 100 percent of all 36 concessions.

The Vizcachitas deposit is in the prolific central Chile Late Miocene-Pliocene metallogenic belt. This belt also includes the world class El Teniente (78.64Mt Cu), Los Pelambres/El Pachon (26.42Mt Cu) and Rio Blanco/Los Bronces (52.43Mt Cu) deposits. The Vizcachitas deposit has the potential for a low strip open pit operation.

The Vizcachitas property contains an NI 43-101 compliant indicated resource of 515M tonnes grading 0.39 percent Cu (4.4 billion pounds) and 0.011 percent Mo (125 million pounds). It contains an inferred sulphide resource of 572M tonnes grading 0.34 percent Cu (4.3 billion pounds) and 0.012 percent Mo (151 million pounds) at a 0.3 percent copper equivalent cut-off.

The Vizcachitas porphyry copper-molybdenum project is in a region of good infrastructure. This infrastructure includes available water, road access to the site, power approximately 40 kilometers away, as well as ports and smelters within 200 kilometers.

Los Andes Copper announced that they received, in August of 2012, $1,950,000 upon the exercise of 13,000,000 stock purchase warrants of the Company. Turnbrook Corp. exercised the Warrants at a price of $0.15 each. These were exercisable on or before December 21, 2013.

Los Andes is using the proceeds received to fund exploration and development work on their Vizcachitas project, and for general working capital purposes.

The principal target of exploration on the Vizcachitas Property is Andean-style porphyry copper - molybdenum deposit. Porphyries usually consist of large masses of hydrothermally altered rock containing quartz veins and stockworks, which include sulfide-bearing veinlets and disseminations, and cover areas up to 10 km2 in size.

Los Andes Copper Ltd. (LA.V), closed Tuesday's trading session at $0.23, even for the day. The stock's 52-week low/high is $0.19/$0.35.

Par Petroleum Corp. (PARR)

Today we are highlighting Par Petroleum Corp. (PARR), here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Par Petroleum Corp. manages and maintains interests in a broad array of energy-related assets. These include natural gas assets located in the Piceance Basin, and a crude oil sourcing, marketing, transportation and logistics business headquartered in Houston, Texas via their wholly-owned subsidiary, Texadian Energy, Inc. Par Petroleum has their corporate headquarters in Houston, Texas.

The Company’s main asset is a 33.34 percent minority ownership interest in a joint venture (JV) entity named Piceance Energy, LLC. The remaining ownership interest is held by Laramie Energy II, LLC, who manages the day-to-day operations of the JV. In addition, Par Petroleum has an interest in the Point Arguello offshore unit in California as well as other miscellaneous assets.

The Company’s Texadian Energy subsidiary sources, markets, transports and distributes crude petroleum-based energy products. Texadian Energy has considerable logistics capabilities in historical pipeline shipping status, a rail car fleet, and expertise in contracted chartering of tows and barges. Texadian has the ability to move crude oil from land locked locations in the Western United States and Canada to the refining hubs in the Midwest, the Gulf Coast, and the East Coast.

Yesterday, Par Petroleum announced that the Company has reached a definitive agreement for the acquisition of Tesoro Hawaii, LLC from Tesoro Corp. Tesoro Hawaii is an owner of refining, retail and distribution assets located in Hawaii. The retail stations will remain under the Tesoro brand following the closing.

The new refining subsidiary (to be based in Houston) will operate as a separate wholly-owned subsidiary of Par Petroleum.  Par Petroleum’s intention is to appoint Mr. William Haywood as President of their new refining subsidiary. Mr. Haywood has over 30 years of experience in domestic and international energy.

Par Petroleum, through a wholly-owned subsidiary, will purchase all outstanding membership interests of Tesoro Hawaii for $75 million in cash, plus net working capital and the market value of inventory at closing. Also included in the purchase price is an earn-out arrangement of up to $40 million payable over three years contingent on certain performance metrics.

Par Petroleum Corp. (PARR), closed Tuesday's trading session at $1.61, up 3.87%, on 1,459,558 volume with 172 trades. The average volume for the last 60 days is 86,548 and the stock's 52-week low/high is $0.06/$1.77.

Propell Technologies Group, Inc. (PROP)

PennyStocks24, PennyStocksWatchman, and ActivePennyStock reported recently on Propell Technologies Group, Inc. (PROP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Propell Technologies Group, Inc., via their wholly owned subsidiary, Novas Energy USA, engages in the commercial application of a proprietary "Plasma-Pulse Technology" (PPT) to enhance the recovery of oil and gas in existing wells. Propell Technologies acquired a specific oil and gas recovery enhancement technology at the end of 2012. This particular technology has been shown to considerably improve existing well recovery and production volumes. Before the acquisition of this technology, the Company’s focus had been in a software technology targeting retail textile sales that had been directed under former management.

The Company’s Novas Energy USA team consists of many Ph.D.’s and hands-on operation professionals within hydrocarbon geological, engineering, field service and economic segments of the oil industry. Novas Energy USA was organized to utilize their proprietary "Plasma-Pulse Technology" to enhance the recovery of oil. The design of their technology is to be suitable for oil wells as deep as 12,000’. The design of it is also to be highly effective, fast and economical.

At the end of May, Propell Technologies Group announced that the Company’s Novas Energy USA subsidiary began treating oil wells with their proprietary plasma pulse technology. On March 19, 2013, Novas treated two oil wells in the Fredericksburg limestone formation near Shreveport, Louisiana. Since these treatments, the operator has made regular reports and also provided testing data through on site "barrel tests." These indicated a substantial rise in oil production.

Both wells on this shallow field (consistent with previous wells treated) responded with an increase in immediate production. The initial treatments completed within a 24-hour period as they worked through the night and successfully pulsed the specific pay zones already in production.

Furthermore, in early June, Novas Energy USA reported feedback from wells treated in the Tulsa, Oklahoma area. They utilized their licensed proprietary and patented plasma pulse technology on two wells in a fairly shallow field at a 2,600 foot depth that appeared to be significantly depleted according to production records. The wells were treated on March 28, and April 16, 2013; the operator has been accumulating production data since.

Propell Technologies Group, Inc. (PROP), closed Tuesday's trading session at $0.85, up 10.82%, on 300,868 volume with 162 trades. The average volume for the last 60 days is 18,997 and the stock's 52-week low/high is $0.012/$1.75.

Arch Therapeutics, Inc. (ARTH)

Today we are reporting on Arch Therapeutics, Inc. (ARTH), here at the QualityStocks Daily Newsletter.

From their corporate headquarters in Natick, Massachusetts, Arch Therapeutics, Inc. operates as a life science company. Arch is a medical device company that offers their unique approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care. Currently, the Company’s products are progressing in preclinical development. The design of their first product, AC5™, is to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. Arch Therapeutics’ shares trade on the OTC Markets’ OTCQB.

The underlying technology is exclusively licensed from a leading university. This technology supports an innovative platform of smart materials that fulfill the criteria as a solution for a specialized field the Company calls, “stasis and barrier applications.”  Arch Therapeutics’ intention is to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Their solution controls the movement of these fluids and substances.

The Company’s AC5™ stops bleeding quickly. It conforms to irregular wound geometry and allows for normal healing. AC5™ helps maintain a clear field of vision directly into the wound area.

In addition, it is not sticky or glue-like. Therefore, it is suited for use in the laparoscopic setting. Moreover, it is transparent; this enables a surgeon to operate through it to prophylactically stop bleeding as it starts. This is a vital advancement that Arch Therapeutics has branded as Crystal Clear Surgery™.

The design of AC5™ itself is at the nano-scale. It is a synthetic peptide consisting of naturally occurring, non-animal, amino acids using straight-forward manufacturing techniques. AC5™ undergoes application directly onto a surgical or traumatic wound, where it quickly creates a physical barrier in the nooks and crannies of the tissue and without delay stops bleeding and fluid leaks. Upon the healing of the incision, AC5™ is naturally absorbed and passes from the body.

Arch Therapeutics, Inc. (ARTH), closed Tuesday's trading session at $0.75, down 2.60%, on 3,823,425 volume with 735 trades. The average volume for the last 60 days is 37,394 and the stock's 52-week low/high is $0.0136/$1.18.

IntelGenx Technologies Corp. (IGXT)

FeedBlitz, Wall Street Resources, and AllPennyStocks reported previously on IntelGenx Technologies Corp. (IGXT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

IntelGenx Technologies Corp. (IGXT) is a drug delivery company with corporate headquarters in Saint Laurent, Province of Quebec. The Company focuses on the development of oral controlled-release products and novel rapidly disintegrating delivery systems. . IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. IntelGenx Technologies’ shares trade on the OTCQX U.S.

The Company’s strategy is to apply their proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in combination with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. IntelGenx Technologies can, via their enterprise and strategic partners, offer their partners full service pharmaceutical development. This runs the gamut from formulation development, clinical development and regulatory activities to manufacturing and packaging.

The Company utilizes their innovative multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. In addition, IntelGenx has developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity; the basis of this is on their experience with rapidly disintegrating films.

Their pipeline includes Forfivo™ - indicated for Major Depressive Disorder; Rizatriptan film – indicated for Migraine; Tadalafil film – indicated for Erectile Dysfunction; INT0028 – indicated for Neuropathic Pain Management, as well as the aforementioned animal health products.

Today, IntelGenx announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) action date of February 3, 2014 for the review of the Company's New Drug Application (NDA) for the marketing approval of IntelGenx' Anti-Migraine VersaFilm™ oral film product. The product is a novel, oral thin-film formulation, based on their proprietary VersaFilm™ technology containing Rizatriptan, the active drug in Merck & Co. Maxalt-MLT® orally disintegrating tablets. The FDA confirmed that IntelGenx' application is sufficiently complete to permit a substantive review in accordance with the FDA's "standard" classification process.

IntelGenx Technologies Corp. (IGXT), closed Tuesday's trading session at $0.605, up 6.14%, on 358,781 volume with 86 trades. The average volume for the last 60 days is 158,123 and the stock's 52-week low/high is $0.45/$0.75.

National Graphite Corp. (NGRC)

Dividend Opportunities reported yesterday on National Graphite Corp. (NGRC), PennyStocks24, The Best Newsletters, Investment House, Market FN, Todd Horwitz, YOLOTraderAlerts, The Trading Report, Stock Research Newsletter, The Stock Enthusiast, Another Winning Trade, InvestorPlace, Stockblogs, Wyatt Investment Research, Trade of the Week, OTC Journal did earlier, and we report on the Company, here at the QualityStocks Daily Newsletter.

National Graphite Corp. is a Graphite, Gold, Silver and precious metals exploration enterprise based in Las Vegas, Nevada. Their focus is acquiring and developing graphite projects for the active end use for graphite - the battery segment. National Graphite is essentially a graphite development company concentrating on bringing the Chedic Graphite Mine back into commercial production to supply this fast growing graphite mineral market.

Graphite is a mineral consisting entirely of carbon. In its standard crystalline state, it is considered the most stable form of carbon. Graphite is an excellent conductor of heat and electricity. Moreover, it has the highest natural strength and stiffness of any material known today. Earlier this month, National Graphite announced that they entered into an agreement with American Graphene LLC where National Graphite and American Graphene will explore joint business opportunities in the emerging graphene market.

National Graphite acquired 65 claims of 60 hectares each for more than 9,600 acres in Lochaber Township in Quebec, and 20 Mineral Lode Claims in Township, 15 North, Range 19 East, Sections 25 & 26 Carson City, Nevada - mining claims consisting of approximately 400 acres.

Currently, the Company holds the rights to the Chedic/Voltaire, past producing, graphite mine in northwest Nevada near Carson City. The Chedic/Voltaire Property consists of 35 unpatented mining claims covering approximately 1.1 square miles.

Pertaining to Precious Metals, National Graphite owns 100 percent interest in two high value properties in Mineral County, Nevada, known as the Candelaria claims. These claims incorporate the Silver Summit acquisition and the Black Butte Mines. These are two historic former producing mines in Nevada's premier Gold and Silver trends.

Their Candelaria silver properties are in the Walker Lane Mineral Belt in western Nevada. The Walker Lane hosts a variety of precious metal and base metal mineral deposits (and geothermal activity) along its length. The mineralization on the Candelaria prospect is primarily silver mineralization with some gold, lead and zinc exposed at the surface.

Today, National Graphite announced the results of testing and analysis of a field sample collected by Mr. William Feyerabend, CPG a qualified independent geologist. The sample was taken to demonstrate the presence and grade of the graphite on the Company’s Chedic/Voltaire Property in Nevada. Graphite carbon analyses of the material by SGS North America, Inc. yielded a grade of 7.0 percent graphite.

National Graphite Corp. (NGRC), closed Tuesday's trading session at $0.188, up 9.94%, on 1,211,920 volume with 154 trades. The average volume for the last 60 days is 146,310 and the stock's 52-week low/high is $0.08/$1.24.

Avita Medical Ltd. (AVMXY)

MissionIR and Tiny Gems reported previously on Avita Medical Ltd. (AVMXY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Avita Medical Ltd. develops and distributes regenerative, tissue-engineered products for treating wounds, burns, scars as well as skin defects. The Company’s patented and proprietary tissue‐culture, collection and application technology provides unique treatment solutions derived from a patient's own skin. Avita Medical lists on the OTCQX International. The Company has offices in Cambridge, UK, Northridge, California, and in Western Australia.

Avita Medical's lead product is ReCell® Spray-On Skin®. It is used in a broad array of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and SFDA‐cleared in China. ReCell is not available for sale in the U.S. In the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is taking place.

ReCell® is a stand-alone, rapid cell harvesting device. It enables surgeons to treat skin defects using the patient's own cells. The surgeon can prepare a small quantity of cells within 30 minutes on site.

Furthermore, the Company has their respiratory products. These are Funhaler and Breath-A-Tech. Their Funhaler is an easy to use small volume spacer. It makes it easier for children to take their aerosol asthma medication.

Avita’s Breath-A-Tech is the proven, effective medication spacer for adults and children. Breath-A-Tech is available to the general public through pharmacies. This compact size product is effective in delivering medication, combined with ease of cleaning and the ability to undergo hospital grade autoclaving.

This past April, Avita Medical announced that they secured the grant of Japanese Patent No. 5214085 "Cell Suspension Preparation Technique and Device" by the Japanese Patent Office.  Japan is the world's third largest healthcare market behind the United States and Europe.

The granted patent protects Avita’s broad claims related to the preparation and composition of a cell suspension consisting of the patient's own epithelial cells (an autologous suspension), and the general therapeutic use of the regenerative epithelial cell suspension. The patented technology is incorporated into Avita Medical’s lead regenerative product, ReCell® Spray-On Skin®.

Avita Medical Ltd. (AVMXY), closed Tuesday's trading session at $2.60, up 13.54%, on 149,120 volume with 115 trades. The average volume for the last 60 days is 9,485 and the stock's 52-week low/high is $1.87/$4.20.

graphic

The QualityStocks
Company Corner

graphic
graphic

The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.42, up 40.00%, on 839,915 volume with 191 trades. The stock’s average daily volume over the past 60 days is 321,438, and its 52-week low/high is $0.21/$1.25.

The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.

Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.

The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.

The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC Begins Brand-Building Wholesale Initiative

ASCC Ready to Hit Market with Top Shelf Vodka Everyone Can Enjoy

ASCC Forms Vodka Distribution Strategy

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.017, up 4.94%, on 10,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 432,481, and its 52-week low/high is $0.001/$0.12.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Enters Partnership Agreement With KO Entertainment, Inc.

Consorteum Holdings Reaches Strategic Partnership Agreement With Knockout Gaming

Consorteum Holdings Inc. Reaches Funding Agreement With Private Equity Group

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.082, up 1.23%, on 1,669,785 volume with 122 trades. The stock’s average daily volume over the past 60 days is 532,601, and its 52-week low/high is $0.06/$0.262.

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013

Cardium Announces Favorable Recommendations From ISS And Glass Lewis For Annual Meeting Proposals

Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments

GRILLiT, Inc. (GRLT)

The QualityStocks Daily Newsletter would like to spotlight GRILLiT, Inc. (GRLT). Today, GRILLiT, Inc. closed trading at $0.44, on 25,955 volume with 12 trades. The stock’s average daily volume over the past 60 days is 3,527, and its 52-week low/high is $0.11/$1.50.

GRILLiT, Inc. (GRLT) was founded on the concept of delivering a fast-casual dining experience with fresh, nutritious home-style cooking. Leveraging more than four decades of experience in the food industry, the founders of GRILLiT established this unique business model to satisfy the ever-increasing demand for delicious and healthy food while providing the perfect ambiance for guest to relax and enjoy great cuisine.

The company sources its ingredients from local and domestic farmers to ensure crisp, fresh produce and grain-fed Angus beef. The cooking techniques and low-sodium recipes employed result in uniquely healthy and delectable meal choices. Using the best possible ingredients, GRILLiT chefs have created an inspiring flavor profile using fresh herbs spices and all-natural marinades.

The management team executing GRILLiT’s business strategy has been carefully assembled to achieve rapid growth and profitability. One of the most recent additions, Rob Elliott, brings more than 25 years of experience in restaurant franchise system development, marketing, branding, and operations. Previously serving as Vice President of Marketing for Little Caesars Pizza, he was instrumental in expanding the number of store locations from 150 to 5,000.

GRILLiT is focused on expanding throughout the southeastern United States and offers nationwide franchising opportunities. Current locations operate in high-traffic shopping plazas and offer American, Asian Fusion, and Latin American food styles. The company’s growth strategy is based on a five-year plan to roll out a total of 79 stores in nine States: Florida, Kentucky, Ohio, New Jersey, New Hampshire, North Carolina, Tennessee, Georgia, and Pennsylvania. Disclaimer

GRILLiT, Inc. Company Blog

GRILLiT, Inc. News:

GRILLiT®, Inc. Announces Common Stock Dividend to its Shareholders

GRILLiT®, Inc. Elects Accompplished Restaurant Veteran As Chairman Of Its Board Of Directors

GRILLiT®, Inc. Announces Marketing Campaign Promoting Healthy Living Lifestyle as Part of its Five Year Roll Out Plan

Cardium Therapeutics, Inc. (CXM) Builds Diverse Portfolio with Broad Commercialization Opportunities

It’s not something you’d expect to find in a regenerative medicine company’s portfolio, but Cardium Therapeutics’ To Go Brands healthy nutraceutical supplement business is complementary to the company’s overarching mission of meeting unmet medical needs as part of an individual’s overall health and wellness.

Cardium in October 2012 acquired the assets, business, and product portfolio of To Go Brands, which develops and markets more than 25 products including nutraceutical powder mixes, supplements, and chews to support healthy lifestyles.

The brand’s Healthy To Go product line offers a host of healthy product offerings distributed through mass food and drug channels at retailers such as Whole Foods, CVS, Kroger, GNC, Vitamin Shoppe, and more.

Within Cardium’s medical opportunities portfolio is its lead commercial product, Excellagen®, topical gel for wound care management. Excellagen is FDA-approved for the marketing and sale in the United States. In addition to its plans to advance Excellagen’s commercial reach in the U.S. and internationally, Cardium plans to develop new extensions for additional wound care applications, and its working to achieve regulatory approval for the marketing and sale of the product in South Korea and the European Union.

The company’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its phase 3 registration study for Generx in Russia.

For more information, visit www.cardiumthx.com or www.togobrands.com

GRILLiT, Inc. (GRLT) is “One to Watch”

GRILLiT was founded on the concept of delivering a fast-casual dining experience with fresh, nutritious home-style cooking. Leveraging more than four decades of experience in the food industry, the founders of GRILLiT established this unique business model to satisfy the ever-increasing demand for delicious and healthy food while providing the perfect ambiance for guest to relax and enjoy great cuisine.

The company sources its ingredients from local and domestic farmers to ensure crisp, fresh produce and grain-fed Angus beef. The cooking techniques and low-sodium recipes employed result in uniquely healthy and delectable meal choices. Using the best possible ingredients, GRILLiT chefs have created an inspiring flavor profile using fresh herbs spices and all-natural marinades.

The management team executing GRILLiT’s business strategy has been carefully assembled to achieve rapid growth and profitability. One of the most recent additions, Rob Elliott, brings more than 25 years of experience in restaurant franchise system development, marketing, branding, and operations. Previously serving as Vice President of Marketing for Little Caesars Pizza, he was instrumental in expanding the number of store locations from 150 to 5,000.

GRILLiT is focused on expanding throughout the southeastern United States and offers nationwide franchising opportunities. Current locations operate in high-traffic shopping plazas and offer American, Asian Fusion, and Latin American food styles. The company’s growth strategy is based on a five-year plan to roll out a total of 79 stores in nine States: Florida, Kentucky, Ohio, New Jersey, New Hampshire, North Carolina, Tennessee, Georgia, and Pennsylvania.

Let us hear your thoughts: GRILLiT, Inc. Message Board

Advaxis, Inc. (ADXS) and Jack Klugman

When well-loved theater and television performer Jack Klugman died in December of 2012 at age 90, few people remembered an important role that the actor played in the country’s drug development process. Klugman, who had gained television fame as Oscar Madison in The Odd Couple, and later as a medical examiner in the long running series Quincy, was one of the earliest stars to use his celebrity to effectively drive social causes.

In 1982, Klugman went to Washington and testified before Congress on behalf of the Orphan Drug Act. The idea was to provide various governmental supports to encourage pharmaceutical companies to invest in developing drugs for relatively small medical markets. Few people were aware of the need for such support until an episode of Quincy was broadcast in 1981, showing how many people suffered from diseases that went unresearched because they were considered unprofitable. Klugman was called to testify in support of the Act in 1982, and was instrumental in finally getting it passed in 1983.

Since the Act became law some 30 years ago, it has helped support the development of hundreds of drugs, drugs that have gone on to help countless people, and it continues to serve today. Most recently, Advaxis, a developer of immunotherapies for cancer and infectious diseases, applied for Orphan Drug Designation with the FDA Office of Orphan Products Development for the company’s ADXS-HPV drug.

ADXS-HPV is being developed for the treatment of human papillomavirus (HPV)-associated head and neck cancer. Although such cancers do not get the publicity or funding associated with more common diseases, it is still estimated that there are 50,000 new cases of head and neck cancer in the U.S. annually, with about 15,000 deaths. Situations such as this are exactly what the law was meant to address. Orphan Drug Designation entitles the sponsor to clinical protocol assistance with the FDA, as well as federal grants, tax credits, and a seven-year market exclusivity period. The new Advaxis drug is good news for sufferers, with the company’s Chief Scientific Officer, Robert Petit, saying: “We believe ADXS-HPV could become an important new non-cytotoxic treatment for patients with HPV-associated head and neck cancer.”

For additional information, visit www.Advaxis.com

International Stem Cell Corp. (ISCO) Stem Cell Technology a Game Changer for Regenerative Medicine

International Stem Cell Corp. is focused on treating diseases of the eye, nervous system, and liver by utilizing a new stem cell technology called parthenogenesis. The regenerative technology uses unfertilized eggs, sidestepping the controversial use of embryo stem cells, to address immune-rejection.

Stem cells not only have the ability to proliferate, but also to change (differentiate) into more specialized cells such as skin, liver, or blood cells. Because these “pluripotent” stem cells have the potential to become any cell in the body, they are considered the most powerful stem cells.

The first type of pluripotent stem cells to be studied were embryonic stem cells, though the process is of considerable ethical question because creating embryonic stem cells involves the destruction of a fertilized human embryo.

As an innovative alternative, ISCO has pioneered the development of human parthenogenetic stem cells (hpSCs), which are created by chemically stimulating unfertilized eggs (oocytes) to initiate division (proliferation). hpSCs are one of four of the most commonly used and described classes of stem cells: embryonic stem cells (embryonic SCs), induced pluripotent stem cells (iPS), and adult stem cells (adult SCs).

The parthenogenetic stem cells developed by ISCO are the only class of cells that meet all the criteria considered for therapeutic applications. The company has developed a UniStemCell bank, the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. The company anticipates that in the medium term, revenue could be generated through the franchise of stem cell banks.

For more information, visit www.internationalstemcell.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Wallstreetlivechat
(JUMT)

2.

PennyStocks24
(VRNI)

3.

OTCJournal
(BZIC)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251